Federated Hermes ETF Trust Federated Hermes Total Return Bond ETF (ARCA: FTRB)

Latest news for Federated Hermes ETF Trust Federated Hermes Total Return Bond ETF (ARCA:FTRB)

The Fund pursues its investment objective by investing primarily in U.S. dollar denominated, investment-grade, fixed-income securities. In addition, the Fund may invest in high-yield, non-U.S. dollar denominated, and emerging market fixed-income securities when Federated Investment Management Company (the Adviser) considers the riskreturn prospects of those sectors to be attractive. The Fund may invest up to 25% of its total assets in noninvestment-grade debt securities (otherwise known as junk bonds). The amount of any unhedged non-U.S. dollar denominated fixedincome securities and foreign currencies in the Funds portfolio will normally not exceed 10% of the Funds total assets.

Ishares Mbs ETF

Federated Hermes Total Return Bond ETF

Federated Hermes ETF Trust Federated Hermes Total Return Bond ETF

Needham analyst Ryan MacDonald reiterates Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) with a Hold.

News

Reiteration

Analyst Ratings

CHGG

Needham Reiterates Hold on Chegg

Shares of Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/general/space/24/11/41922070/rocket-lab-q3-earnings-revenue-beat-eps-beat-continued-strong-demand-growth-multi-launch-agreement-air-force-award-and-more">third-quarter financial results</a>.
The company also announced a multi-launch agreement with a confidential commercial satellite constellation operator and was awarded a federal defense contract worth up to $8 million.
Rocket Lab USA shares jumped 28.7% to $18.86 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Microvast Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) gained 79.5% to $0.3244 in pre-market trading after the company reported better-than-expected third-quarter financial results.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) gained 62.6% to $0.6682 in pre-market trading after the company reported better-than-expected quarterly financial results.</li>
<li>Nature&#8217;s Miracle Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) rose 56% to $0.1337 in pre-market trading. Nature&#8217;s Miracle announced the closing of $3.0 million public offering.</li>
<li>Dave Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) gained 37.3% to $86.21 in pre-market trading after the company reported a profit for the third quarter.</li>
<li>Paymentus Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) climbed 27.8% to $34.02 in pre-market trading following strong earnings and guidance.</li>
<li>Kairos Pharma, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#NYSE">KAPA</a>) gained 26.1% to $2.59 in pre-market trading after jumping 51% on Tuesday.</li>
<li>Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) gained 20.1% to $3.58 in pre-market trading. Mullen Automotive shares jumped 74% on Tuesday after the company announced its Class 1 EV cargo van is listed for vehicle rental on Turo.</li>
<li>WM Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAPS#NASDAQ">MAPS</a>) rose 19.9% to $0.8585 in pre-market trading after the company reported better-than-expected third-quarter revenue results and issued fourth-quarter revenue guidance above estimates.</li>
<li>Hallador Energy Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNRG#NASDAQ">HNRG</a>) gained 14.2% to $11.93 in pre-market trading following third-quarter earnings.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Syros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) shares tumbled 81% to $0.5199 in pre-market trading after the company announced its SELECT-MDS-1 Phase 3 trial of tamibarotene did not meet its primary endpoint and has discontinued the study.</li>
<li>Spirit Airlines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>) shares fell 62.4% to $1.21 in pre-market trading after the company failed to file its earnings for the quarter ended September 2024. The discount airline in a filing late Tuesday, said that it is in talks with its creditors to carve out a restructuring plan which could lead to the cancellation of its equity shares.</li>
<li>Sidus Space, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) declined 44.8% to $1.24 in pre-market trading after the company priced its $7 million public offering of 5.6 million common shares at $1.25 each.</li>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) shares fell 43% to $0.6100 in pre-market trading after dipping 46% on Tuesday.</li>
<li>Vroom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRM#NASDAQ">VRM</a>) fell 32.8% to $5.96 in pre-market trading following third-quarter results.</li>
<li>Nano Labs Ltd  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) dipped 23.3% to $5.90 in pre-market trading after jumping 134% on Tuesday. The company recently said it will start accepting payments in Bitcoin.</li>
<li>i-80 Gold Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAUX#NYSE">IAUX</a>) fell 21.3% to $0.7150 in pre-market trading after posting third-quarter results.</li>
<li>Groupon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) shares dipped 21.4% to $8.90 in pre-market trading after reporting third-quarter results.</li>
<li>Next Technology Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) fell 21.2% to $1.60 in today's pre-market trading after jumping over 76% on Tuesday.</li>
<li>ZoomInfo Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) fell 13.8% to $11.28 in pre-market trading following third-quarter results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41929909/dow-sp-decline-ahead-of-key-inflation-data-tesla-trump-media-slides-fear-index-remains-in-greed-zone">Dow, S&amp;P Decline Ahead Of Key Inflation Data, Tesla, Trump Media Slides: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

CYCC

DAVE

EFSH

GRPN

HNRG

IAUX

KAPA

MAPS

MULN

MVST

NMHI

Next Technology Holding Inc. - Ordinary Shares

NXTT

RKLB

SAVE

SIDU

SYRS

Why Rocket Lab Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket

Needham analyst Gil Blum reiterates Fate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) with a Hold.

FATE

Needham Reiterates Hold on Fate Therapeutics

Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) with a Buy and maintains $23 price target.

Price Target

NMRA

Needham Reiterates Buy on Neumora Therapeutics, Maintains $23 Price Target

Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 26.47 percent increase over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $1.17 million which beat the analyst consensus estimate of $1.14 million by 2.82 percent. This is a 49.68 percent increase over sales of $783.00 thousand the same period last year.

Earnings

LUCD

Lucid Diagnostics Q3 2024 GAAP EPS $(0.25) Misses $(0.22) Estimate, Sales $1.17M Beat $1.14M Estimate

Needham analyst Serge Belanger reiterates Viridian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) with a Buy and maintains $38 price target.

VRDN

Needham Reiterates Buy on Viridian Therapeutics, Maintains $38 Price Target

NTCT

Arelion Announced It Has Expanded Its Partnership With NETSCOUT Cybersecurity And DDoS Attack Protection Solutions, To Strengthen The Internet Carrier's DDoS Attack Mitigation Capabilities

Unbabel, a startup based in Lisbon, has introduced a new AI-powered translation service called Widn.AI. The company&#8217;s CEO, Vasco Pedro, predicts that human translators might become obsolete within the next three years.
What Happened: The Widn.AI service utilizes Unbabel&#8217;s proprietary large language model, Tower, which can handle translations in 32 different languages. Pedro shared these insights during an interview at the Web Summit in Lisbon, highlighting the advancements in AI since Unbabel was founded a decade ago, CNBC <a href="https://www.cnbc.com/2024/11/13/unbabel-launches-ai-translation-app-looks-for-fresh-funding.html">reported </a>on Wednesday.
Initially, Unbabel&#8217;s approach combined AI with human editors for translations. However, Pedro now believes AI can manage most translation tasks independently, &#8220;except for really the &#8230; most difficult use cases,&#8221; and is nearing full capability.
See Also: <a href="https://www.benzinga.com/24/11/41868085/new-head-strap-for-apple-vision-pro-election-tracking-ai-magic-and-more-this-week-in-appleverse?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">New Head Strap For Apple Vision Pro, Election Tracking, AI Magic, And More: This Week In Appleverse</a>
Despite a potential decline in revenue per translated word, Pedro anticipates that an increase in the volume of translated content will drive growth. Unbabel is currently seeking $20 million to $50 million in funding to further develop and expand Widn.AI.
Why It Matters: The launch of Widn.AI and Pedro&#8217;s bold prediction comes amid ongoing debates about the impact of AI on employment. Vinod Khosla, a Silicon Valley billionaire, recently forecasted that AI could replace a significant portion of human jobs <a href="https://www.benzinga.com/personal-finance/24/10/41196355/ai-will-do-most-jobs-better-faster-cheaper-silicon-valley-billionaire-vinod-khosla-calls-for-uni">over the next 25 years</a>. He suggested that AI might perform 80% of tasks in 80% of jobs, including roles like primary care doctors and assembly line workers.
However, Sam Altman, CEO of ChatGPT-maker OpenAI, has downplayed the<a href="https://www.benzinga.com/news/24/09/41082791/sam-altman-dismisses-ai-job-threat-urges-next-generation-to-embrace-the-technology"> threat of AI-induced unemployment</a>. Altman encourages the next generation to embrace AI technology, believing that while some jobs may change, new opportunities will arise. This optimistic view contrasts with Khosla&#8217;s warning that workers might not be able to upgrade their skills to avoid job losses.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/media/24/11/41873261/apples-ios-18-1-update-adds-inactivity-reboot-to-lock-down-unused-iphones-heres-how-it-protects-your-privacy?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple&#8217;s iOS 18.1 Update Adds &#8216;Inactivity Reboot&#8217; To Lock Down Unused iPhones — Here&#8217;s How It Protects You</a></li>
</ul>
Image via GoodFon/ Gottlib
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Tech

General

AI Coming For Translator Jobs? This CEO Says Humans Won't Be Needed For Translation 'Except...Most Difficult Use Cases' In 3 Years

Piper Sandler analyst Clarke Jeffries maintains Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) with a Overweight and raises the price target from $93 to $120.

FOUR

Piper Sandler Maintains Overweight on Shift4 Payments, Raises Price Target to $120

General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) on Tuesday debuted its new electric vehicle under its luxury brand Cadillac &#8211; a three-row SUV set to rival Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Model X and Lucid Group Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) Gravity SUV.
What Happened: The 2026 Cadillac Vistiq will be sold globally, including in the U.S. and Canada, the brand said, while adding that production will commence in early 2025 at General Motors' Spring Hill Manufacturing plant in Tennessee.
The Cadillac Vistiq, it said, will be available in three trims at launch. A new trim will be launched in summer 2025 with added performance elements, it said.
The vehicle will start at $78,790, placing it in the same price range as Tesla&#8217;s Model X and Lucid&#8217;s Gravity SUV. While the Model X is already with customers and driving on roads, the <a href="https://www.benzinga.com/24/11/41838253/lucid-rises-nearly-5-in-pre-market-after-strong-q3-results-opening-orders-for-gravity-suv">start of production for the Gravity SUV</a> is slated for the upcoming weeks. 
The base version of the Model X starts at $79,990 in the U.S. The lower-priced <a href="https://www.benzinga.com/news/24/10/41617327/lucid-to-start-taking-orders-for-gravity-suv-next-week-but-only-for-premium-variant-priced-at-about">Touring trim of the Gravity</a>, meanwhile, is expected to start at $79,900.
Why It Matters: Earlier this month, GM said that it has <a href="https://www.benzinga.com/news/24/11/41736208/gm-crosses-300k-ev-deliveries-in-us-since-2016-but-its-still-over-40-lower-than-teslas-sales-in-the">surpassed selling its 300,000th electric vehicle</a> in the U.S. since 2016.
In the third quarter, GM became the second best-seller of EVs in the U.S. after Tesla by selling over 32,000 EVs. The Cadillac Lyriq was also one of the best-selling EVs from the automaker in the quarter.
&#8220;We are on track to produce and wholesale approximately 200,000 EVs this year and reach variable profit positive in Q4. Our EV momentum is growing,&#8221; GM CFO&nbsp;Paul A Jacobson&nbsp;<a href="https://www.benzinga.com/markets/equities/24/10/41485013/gm-accelerates-its-ev-ambitions-after-a-strong-q3-in-us-powers-it-past-ford-aims-for-200k-wholes" target="_blank" rel="noreferrer noopener">said&nbsp;</a>during the company's third-quarter earnings call last month.
GM CEO Mary Barra then noted that EV demand is "much stronger among<a href="https://www.benzinga.com/news/24/07/39612749/60-000-cadillac-lyriq-drives-gms-q2-ev-sales-after-bolt-is-discontinued" target="_blank" rel="noreferrer noopener">&nbsp;luxury customers&nbsp;</a>than the mainstream market."
"These customers want beautiful designs, advanced technology, performance, and range, everything Cadillac delivers with the LYRIQ, OPTIQ, VISTIQ, and the Escalade IQ," Barra said.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/41930900/marques-brownlee-apologises-for-overspeeding-in-recent-dji-sponsored-video-cuts-off-snippet-of-driving-a-lamborghini-at-96-mph-in-35-mph-zone">Marques &#8216;MKBHD&#8217; Brownlee Apologizes For Overspeeding In Recent Video, Cuts Off Snippet Of Driving A Lamborghini At 96 MPH In 35 MPH Zone</a></li>
</ul>
Photo courtesy: Cadillac

LCID

TSLA

GM Unveils 2026 Cadillac Vistiq Electric SUV With Starting Price Below Tesla Model X, Lucid Gravity

Stephens &amp; Co. analyst Jim Salera reiterates First Watch Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) with a Overweight and maintains $25 price target.

FWRG

Stephens & Co. Reiterates Overweight on First Watch Restaurant Gr, Maintains $25 Price Target

Needham analyst Joseph Stringer reiterates Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Buy and maintains $60 price target.

Needham Reiterates Buy on Avidity Biosciences, Maintains $60 Price Target

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) with a Buy and maintains $14 price target.

GEVO

HC Wainwright & Co. Reiterates Buy on Gevo, Maintains $14 Price Target

Goldman Sachs analyst Stephen Laszczyk maintains Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) with a Buy and raises the price target from $132 to $148.

Goldman Sachs Maintains Buy on Live Nation Entertainment, Raises Price Target to $148

Goldman Sachs analyst Richard Edwards maintains On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) with a Buy and raises the price target from $50 to $57.

ONON

Goldman Sachs Maintains Buy on On Holding, Raises Price Target to $57

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) with a Buy and maintains $32 price target.

KURA

HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target

Evercore ISI Group analyst Eric Boyes initiates coverage on Axalta Coating Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>) with a Outperform rating and announces Price Target of $47.

Initiation

AXTA

Evercore ISI Group Initiates Coverage On Axalta Coating Sys with Outperform Rating, Announces Price Target of $47

Needham analyst Serge Belanger maintains Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) with a Buy and lowers the price target from $5 to $4.

HRTX

Needham Maintains Buy on Heron Therapeutics, Lowers Price Target to $4

The founders of prominent venture capital firm Andreessen Horowitz are observing a plateau in <a href="https://www.benzinga.com/topic/artificial-intelligence">artificial intelligence</a> capabilities, citing data shortages and computational limitations as key barriers to continued rapid advancement.
What Happened: Speaking on a podcast <a href="https://www.youtube.com/watch?v=hookUj3vkE4">released</a> last week, Marc Andreessen noted that while OpenAI&#8216;s GPT-3.5 was once significantly ahead of competitors, &#8220;Sitting here today, there&#8217;s six that are on par with that. They&#8217;re sort of hitting the same ceiling on capabilities.&#8221;
This observation aligns with recent statements from Ilya Sutskever, co-founder of OpenAI and Safe Superintelligence (SSI), who acknowledged that results from traditional AI scaling approaches have plateaued. &#8220;The 2010s were the age of scaling, now we&#8217;re back in the age of wonder and discovery once again,&#8221; Sutskever said in an interview with Reuters.
Despite these challenges, Andreessen Horowitz maintains a significant investment in AI. The firm has even established a GPU lending program to address the critical shortage of computing hardware.
Ben Horowitz highlighted multiple infrastructure challenges beyond chip availability. &#8220;Once they get chips we&#8217;re not going to have enough power, and once we have the power we&#8217;re not going to have enough cooling,&#8221; he explained.
See Also: <a href="https://www.benzinga.com/tech/24/11/41927135/greg-brockman-returns-to-work-at-chatgpts-parent-company-back-to-building-openai">Greg Brockman Returns To Work At ChatGPT&#8217;s Parent Company: &#8216;Back To Building OpenAI&#8217;</a>
Why It Matters: Data scarcity presents another significant hurdle. According <a href="https://www.dataprovenance.org/consent-in-crisis-paper">to</a> the Data Provenance Initiative, between April 2023 and 2024, websites restricted 5% of all data and 25% of high-quality data sources from AI training use. This limitation has led to an unexpected trend: AI companies are hiring human experts to generate training data manually.
&#8220;The big models are trained by scraping the internet&#8230;and there&#8217;s just literally only so much of that,&#8221; Andreessen noted. He pointed out the irony that AI companies are now &#8220;hiring thousands of programmers and doctors and lawyers to actually handwrite answers to questions&#8221; for training purposes.
This situation has created what Andreessen describes as an &#8220;AI hiring boom,&#8221; contrasting with widespread concerns about AI-driven job displacement. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41931788/nvidia-set-for-major-surge-to-204-analyst-predicts-post-q3-boost-driven-by-blackwell-gpu-demand-strong-margins">Nvidia Set For Major Surge To $204? Analyst Predicts Post-Q3 Boost Driven By Blackwell GPU Demand, Strong Margins</a></li>
</ul>
Image Via Shutterstock 
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

AI Capabilities Plateauing, Say Andreessen Horowitz Founders, Echoing Concerns Of OpenAI Co-Founder Ilya Sutskever

Needham analyst Charles Shi reiterates Camtek (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMT#NASDAQ">CAMT</a>) with a Buy and maintains $95 price target.

CAMT

Needham Reiterates Buy on Camtek, Maintains $95 Price Target

In this video, I analyze some recently-launched ETFs from Allianz Investment Management, DoubleLine, and Federated Hermes.

Comments

Federated Hermes ETF Trust Federated Hermes Total Return Bond ETF

News

Latest news for Federated Hermes ETF Trust Federated Hermes Total Return Bond ETF (ARCA:FTRB)

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga